Therapeutic Potential¹

• A feature that makes a TAA ideal for immunotherapy is the dependency of the malignant cells on the expression of the TAA.
• Targeting TAAs that drive the proliferation of the malignant clone will not only contribute to the reduction of the disease burden, but may eliminate the underlying malignant clone/stem cell, which must ultimately be eradicated for achieving cure.

Tumor Dependency:

The tumor dependency approach has produced new targeted therapies which may address one or more of the biological hallmarks of cancer which tumors exploit to proliferate, such as, resisting cell death (avoiding apoptosis) sustaining proliferative signaling, evading growth suppressors, enabling replicative immortality.² The ability of tumor cell populations to expand in number is determined not only by the rate of cell proliferation (cell replication) but also by the rate of cell attrition (cell death):²

• Apoptosis, or programmed cell death, represents a major source of cell attrition.²
  • Sensors (intrinsic or extrinsic) are responsible for monitoring the extracellular and intracellular environment for conditions of normality or abnormality that influence whether a cell should live or die; these sentinels include cell surface receptors that bind survival or death factors.²
  • Effectors (capsases) are regulated by the sensors and ultimately carry out the execution of the death program through selective destruction of subcellular structures and organelles and of the genome.²
  • The BCL-2 family of proteins in the intrinsic apoptosis pathway are "sensors" or "regulators" which control cell death primarily by direct binding interactions that regulate mitochondrial outer membrane permeabilization (MOMP) leading to the irreversible release of cytochrome C, subsequent caspase ("effectors") activation, and the resulting apoptosis.³
  • The tumor necrosis factor (TNF) protein receptor superfamily in the extrinsic apoptosis pathway includes tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 (DR4 and DR5) that when bound to their ligands, induce the ultimate activation of the downstream caspases leading to apoptosis.^4,5

• Epigenetic regulation, including acetylation and other histone modifications, control essential transcriptional regulatory processes in the cell.⁶
  • The bromodomain and extraterminal (BET) family proteins associate with transcriptional activation through interaction with acetylated chromatin, therefore playing a key role as epigenetic regulators.⁷
  • Bromodomains, which are proteins with acetyl-lysine binding modules, function as the principal mediators of molecular recognition of acetylated chromatin and therefore have a key role in transcriptional activation.⁷
  • Bromodomains of BET proteins bind to acetylated chromatin during interphase but also remain attached to chromosomes during mitosis.⁶
  • BET proteins play a prominent role in cell proliferation.⁶

Therapeutic Potential

• Acquired resistance to apoptosis is a hallmark of most, if not all types of cancer.²
  • In cancer, apoptosis evasion through dysregulation of specific BCL-2 family genes is a recurring event.⁸
  • Dysregulation of the apoptotic pathways can not only promote tumorigenesis, but can also render cancer cells resistant to conventional anti-cancer agents, since chemotherapy- and radiotherapy-induced killing of cancer cells is mainly mediated through activation of apoptosis.⁹
• Overexpression of anti-apoptotic BCL-2 family proteins (BCL-2, BCL-XL, BFL-1/A1, BCL-W and MCL-1) disrupts the dynamic balance of anti- and pro-apoptotic proteins, which may promote cancer cell survival.^9,10
  • The overexpression of these proteins is seen in a wide variety of hematologic malignancies and solid tumors.^9,11
  • The heterogeneity among tumors, even of the same type, necessitates a continued effort to further investigate mechanisms of apoptosis dysregulation in distinct cancer cell types.⁹
• Strategies to inhibit anti-apoptotic BCL-2 proteins include reducing protein expression by targeting the corresponding mRNA with an antisense oligonucleotide compound as well as blocking anti-apoptotic activity by targeting at the protein level.^9,10
  • There is interest in developing drugs that mimic the action of the BH3 domain by binding to one or more of the BCL-2-like proteins and triggering the apoptotic program.¹⁰
• TRAIL is an important immune effector molecule in the surveillance and elimination of developing tumors, therefore, inactivation of the TRAIL pathway and/or escape from TRAIL-mediated immunosurveillance might have an important role in tumor onset, progression, and treatment resisitance.¹²
  • TRAIL can bind as a trimer to any of four membrane-bound and one soluble receptor, but only the two closely related cell surface death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) with intracellular functional death domains (DDs) that can induce apoptosis of tumor cells.⁴
  • Studies have demonstrated that TRAIL-R1 and R2 receptor agonists (TRAs) are generally well tolerated and that TRAIL can selectively trigger apoptosis in tumor cells across a wide range of tumor types, including colorectal cancer, lung cancer, pancreatic cancer, acute myeloid leukemia and non-Hodgkin lymphoma, without affecting normal cells.^12-16
• BET family proteins are involved in promoting aberrant oncogene expression in a variety of cancers.^16-19
  • Overexpression and gain-of-function mutations of BET proteins can alter gene transcription, histone modification, DNA repair, and apoptosis.²⁰
  • BET proteins serve to regulate the expression of important oncogenes, including those involved in apoptosis as well as cell cycle progression.⁷
  • Aberrant BRD4 expression contributes to carcinogenesis by mediating hyperacetylation of the chromatin containing the cell proliferation-promoting genes.^20,21
  • Genetic rearrangements of BRD-containing proteins have been linked to the development of a number of extremely aggressive tumors.²²
  • Small molecule inhibition of BET proteins have been investigated and demonstrate promising activity in both solid and hematologic malignancies.⁷